Dana Pizzuti - 24 Jun 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Signature
Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
24 Jun 2024
Net transactions value
-$273,980
Form type
4
Filing time
25 Jun 2024, 17:03:15 UTC
Previous filing
17 Apr 2024
Next filing
05 Jul 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $160,455 +9,500 +34% $16.89 37,286 24 Jun 2024 Direct
transaction CRNX Common Stock Sale $434,435 -9,500 -25% $45.73 27,786 24 Jun 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock option (Right to Buy) Options Exercise $0 -9,500 -5.4% $0.000000 167,792 24 Jun 2024 Common Stock 9,500 $19.73 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $45.73 per share. The range of sales prices on the transaction date was $45.53 to $45.88 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
F2 The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.